Infinity Pharma (INFI) Misses Q2 EPS by 14c

Infinity Pharma (NASDAQ: INFI) reported Q2 EPS of ($0.34), $0.14 worse than the analyst estimate of ($0.20).

Infinity expects to end 2017 with a cash, cash equivalents and available-for-sale securities balance ranging from $40 million to $50 million.

For earnings history and earnings-related data on Infinity Pharma (INFI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery